# Enzalutamide & Dutasteride/Finasteride as 1st Line Treatment for Patients =/> 65 Years Old With Prostate Cancer.

> **NCT02213107** · PHASE2 · COMPLETED · sponsor: **University of Rochester** · enrollment: 43 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Enzalutamide and Dutasteride or finasteride

## Key facts

- **NCT ID:** NCT02213107
- **Lead sponsor:** University of Rochester
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09
- **Primary completion:** 2023-10-31
- **Final completion:** 2023-10-31
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2024-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02213107

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02213107, "Enzalutamide & Dutasteride/Finasteride as 1st Line Treatment for Patients =/> 65 Years Old With Prostate Cancer.". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT02213107. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*